Authors: Raffaele Rauso Giulio Gherardini Manfredi Greco Gianpaolo Tartaro
Publish Date: 2011/05/06
Volume: 35, Issue: 7, Pages: 553-556
Abstract
The development of effective antiretroviral therapies for the treatment of human immunodeficiency virus HIV has drastically changed the management of infected patients 1 with treatment methods now being similar to those of chronic disease rather than fatal illness As rates of opportunistic infections and other conditions associated with immunodeficiency are minimized patients are able to live longer with more fulfilling lives However these therapies are not without side effects some of which can be very debilitating One medicationassociated condition that has become prevalent among HIVinfected patients is HIVassociated lipodystrophy a syndrome characterized by abnormal fat metabolism and deposition 2 Rates of lipodystrophy have been reported in 18–70 of patients taking protease inhibitors 3 Clinically the condition manifests as serum metabolic abnormalities and body fat redistribution characterized by both lipoatrophy in the face and extremities and
Keywords: